The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Mar. 28, 2023
Filed:
Dec. 23, 2020
Applicant:
Industrial Technology Research Institute, Hsinchu, TW;
Inventors:
Ping-Fu Cheng, Taipei, TW;
Ya-Ling Chiu, Hsinchu, TW;
Kang-Li Wang, Kaohsiung, TW;
Po-Yen Lin, Hsinchu, TW;
Shih-Ta Chen, New Taipei, TW;
Tseng-Huang Liu, Kaohsiung, TW;
Pei-Shin Jiang, Hsinchu, TW;
Assignee:
INDUSTRIAL TECHNOLOGY RESEARCH INSTITUTE, Hsinchu, TW;
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C12N 15/115 (2010.01); A61K 47/54 (2017.01); A61P 35/00 (2006.01); A61K 9/00 (2006.01); C12N 15/113 (2010.01);
U.S. Cl.
CPC ...
C12N 15/115 (2013.01); A61K 9/0019 (2013.01); A61K 47/549 (2017.08); A61P 35/00 (2018.01); C12N 15/1138 (2013.01); C12N 2310/16 (2013.01); C12N 2310/31 (2013.01); C12N 2310/315 (2013.01); C12N 2310/3519 (2013.01); C12N 2320/32 (2013.01);
Abstract
A nucleic acid-drug complex is provided in the present disclosure, which includes a nucleic acid sequence of an anti-PD-L1 aptamer and a CpG oligonucleotide sequence capable of activating TLR9, in which the CpG oligonucleotide sequence consists of a first fragment and a second fragment, and the nucleic acid sequence of the anti-PD-L1 aptamer is inserted between the first fragment and the second fragment.